Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST266 for Persistent Corneal Epithelial Defects
NCT03687632Phase 2Completed
- Sponsor
- Noveome Biotherapeutics
- Start
- Jun 2019
- Primary completion
- Aug 2020
- Modality
- Cytokines & Interferons, Hormones & Growth Factors
- Countries
- 1
01
Overview
A Phase 2 trial of ST266 in persistent corneal epithelial defect (PED), sponsored by Noveome Biotherapeutics. Started Jun 2019; status: completed.
02
Drugs
ST266
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT03687632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687632.